血清 sCD25 是类风湿关节炎相关间质性肺疾病的一个指标。
Serum sCD25 is an indicator for rheumatoid arthritis-associated interstitial lung disease.
机构信息
Department of Rheumatism and Immunology, First Affiliated Hospital of Xinjiang Medical University, Xinjiang, China.
Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, and Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135), Beijing, China.
出版信息
Clin Exp Rheumatol. 2024 Mar;42(3):633-641. doi: 10.55563/clinexprheumatol/3iqvk3. Epub 2023 Sep 22.
OBJECTIVES
CD25 (IL-2Rα) is one of IL-2 receptor's polypeptide subunits, and its soluble form is increased in patients with various inflammatory or autoimmune diseases. This study aimed to evaluate the clinical correlation of serum soluble CD25 (sCD25) with interstitial lung disease (ILD) in rheumatoid arthritis (RA) patients.
METHODS
294 RA patients, including 72 in the discovery cohort (15 patients with ILD, 57 patients without ILD), 222 in the validation cohort (41 patients with ILD and 181 patients without ILD), and 58 healthy controls (HCs) were recruited. High-resolution computed tomography (HRCT) scan provided evidence and patterns of RA-ILD. Serum sCD25 concentrations were measured by enzyme-linked immunosorbent assay (ELISA). Clinical and laboratory data were recorded and the association with sCD25 was also analysed.
RESULTS
In the discovery cohort, 16 RA-related molecules including cytokines, chemokines and functional soluble cell surface proteins were investigated. The results showed that sCD25 was significantly higher in RA-ILD than in RA-no-ILD group (p=0.004). ROC analysis also showed RA-ILD was discriminated with RA-no-ILD by sCD25 (AUC=0.695, 95% CI=0.541-0.849). Logistics regression demonstrated that sCD25 was one of the risk factors of RA-ILD. This result was further confirmed in validation cohort (p<0.001). According to the cut-off value in the discovery cohort, the sensitivity and specificity of sCD25 in RA-ILD were 51.2%, 77.3%, respectively. Compared with RA-no-ILD, serum level of sCD25 was also higher in different HRCT patterns including UIP, NSIP and RA-ILA. The ROC curves revealed sCD25 as diagnostic marker in UIP, NSIP and RA-ILA (with AUCs of 0.730, 0.761, and 0. 694, respectively, p<0.05). The result indicated that sCD25 was a biomarker for RA-ILD subtypes. Although sCD25 was not correlated with HRCT scores, it was significantly higher in consolidation pattern by HRCT.
CONCLUSIONS
sCD25 was significantly elevated in RA-ILD (including UIP, NSIP and RA-ILA) compared to RA-no-ILD and HCs, which supports their value as a potential biomarker in RA-ILD screening and assessment.
目的
CD25（白细胞介素-2 受体α）是白细胞介素-2 受体的多肤亚单位之一，其可溶性形式在各种炎症或自身免疫性疾病患者中增加。本研究旨在评估血清可溶性 CD25（sCD25）与类风湿关节炎（RA）患者间质性肺病（ILD）的临床相关性。
方法
共纳入 294 例 RA 患者，包括发现队列中的 72 例（ILD 患者 15 例，无 ILD 患者 57 例）、验证队列中的 222 例（ILD 患者 41 例，无 ILD 患者 181 例）和 58 例健康对照者（HCs）。高分辨率计算机断层扫描（HRCT）扫描提供了 RA-ILD 的证据和模式。通过酶联免疫吸附试验（ELISA）测量血清 sCD25 浓度。记录临床和实验室数据，并分析其与 sCD25 的相关性。
结果
在发现队列中，研究了 16 种与 RA 相关的分子，包括细胞因子、趋化因子和功能性可溶性细胞表面蛋白。结果显示，ILD 患者的 sCD25 明显高于无 ILD 患者（p=0.004）。ROC 分析还显示，sCD25 可区分 RA-ILD 与无 ILD（AUC=0.695，95%CI=0.541-0.849）。逻辑回归表明，sCD25 是 RA-ILD 的危险因素之一。这一结果在验证队列中进一步得到证实（p<0.001）。根据发现队列中的截断值，sCD25 在 RA-ILD 中的灵敏度和特异性分别为 51.2%、77.3%。与无 ILD 患者相比，sCD25 在 UIP、NSIP 和 RA-ILA 等不同 HRCT 模式中的血清水平也较高。ROC 曲线显示，sCD25 是 UIP、NSIP 和 RA-ILA 的诊断标志物（AUC 值分别为 0.730、0.761 和 0.694，p<0.05）。结果表明，sCD25 是 RA-ILD 亚型的生物标志物。尽管 sCD25 与 HRCT 评分无相关性，但在 HRCT 中，其在实变模式下的水平明显升高。
结论
与无 ILD 和 HCs 相比，sCD25 在 RA-ILD（包括 UIP、NSIP 和 RA-ILA）中显著升高，这支持其作为 RA-ILD 筛查和评估潜在生物标志物的价值。
Zotero 插件